The BioFire® FilmArray® Blood Culture Identification 2 Panel

Early identification and treatment of sepsis are essential to combat one of the leading causes of hospital patient deaths.1 With 43 targets, the expanded and FDA-cleared BioFire® Blood Culture Identification 2 (BCID2) Panel detects pathogens and antimicrobial resistance genes directly from positive blood cultures.

Blood Culture ID

BioFire BCID2 Panel: 43 Targets. 1 Test. About 1 Hour.

The BioFire BCID2 Panel tests for 43 targets associated with bloodstream infections, including gram-negative bacteria, gram-positive bacteria, yeast, and 10 antimicrobial resistance genes—all with one test and with results available in about an hour from positive blood culture.

The BioFire BCID2 Panel features broadened inclusivity for Enterobacterales, new assays for fungal and anaerobic pathogens, and additional identification of coagulase-negative Staphylococcus species. The BioFire BCID2 Panel menu includes seven additional resistance genes, including carbapenemases and colistin resistance genes. An MREJ assay allows for more specific MRSA identification.

GET PRICING

The BioFire BCID2 Panel Menu

Overall 99.0% Sensitivity and 99.8% Specificity2
Sample Type: Positive blood culture

GRAM-NEGATIVE BACTERIA:

  • Acinetobacter calcoaceticus-baumannii complex
  • Bacteroides fragilis
  • Enterobacterales
    • Enterobacter cloacae complex
    • Escherichia coli
    • Klebsiella aerogenes
    • Klebsiella oxytoca
    • Klebsiella pneumoniae group
    • Proteus spp.
    • Salmonella spp.
    • Serratia marcescens
  • Haemophilus influenzae
  • Neisseria meningitidis
  • Pseudomonas aeruginosa
  • Stenotrophomonas maltophilia

GRAM-POSITIVE BACTERIA:

  • Enterococcus faecalis
  • Enterococcus faecium
  • Listeria monocytogenes
  • Staphylococcus spp.
    • Staphylococcus aureus
    • Staphylococcus epidermidis
    • Staphylococcus lugdunensis
  • Streptococcus spp.
    • Streptococcus agalactiae
    • Streptococcus pneumoniae
    • Streptococcus pyogenes

YEAST:

  • Candida albicans
  • Candida auris
  • Candida glabrata
  • Candida krusei
  • Candida parapsilosis
  • Candida tropicalis
  • Cryptococcus (C. neoformans/C. gattii)

ANTIMICROBIAL RESISTANCE GENES:

  • Carbapenemases
    • IMP
    • KPC
    • OXA-48-like
    • NDM
    • VIM
  • Colistin Resistance
    • mcr-1
  • ESBL
    • CTX-M
  • Methicillin Resistance
    • mecA/C
    • mecA/C and MREJ (MRSA)
  • Vancomycin Resistance
    • vanA/B

Enhanced Antimicrobial Stewardship

The IDSA recommends the addition of rapid diagnostic testing to an effective Antimicrobial Stewardship Program.3 A study at the Mayo Clinic shows that pairing the BioFire® FilmArray® Blood Culture Identification (BCID) Panel with antimicrobial stewardship provides the greatest benefit.4

Adapted from Banerjee R, et al. Clinical Infectious Diseases 2015;61(7):1

33.5 hours faster

Shorten Time to Optimal Therapy

The BioFire BCID Panel and antimicrobial stewardship interventions decreased time to optimal therapy by 33.5 hours.1

Reduce Hospital Costs

Faster organism identification and reduced time to optimal therapy can also lead to better economic outcomes. BioFire BCID Panel identification of coagulase-negative staphylococci contaminants resulted in shorter post-culture length of stay and saved roughly $30,000 per 100 patients tested.5

The BioFire BCID Panel, combined with antimicrobial stewardship, achieved >$3,000 per patient in overall hospital savings5**

** Outcomes from patients with blood cultures growing gram-positive cocci and Candida.

“Adding the BCID to our ASP intervention was clearly beneficial, as time to effective therapy and time to first antimicrobial de-escalation occurred more rapidly, and utilization of narrow-spectrum therapies significantly increased, with no harmful effects on patient care.”2

– Medical University of South Carolina
Charleston, SC

How to Order Reagents

To order the BioFire BCID2 Panel, contact your regional sales representative or use the following contact information:

Product Information

Product NamePart NumberQuantity
BioFire BCID2 Panel ReagentsRFIT-ASY-014730-Pack

Don’t Guess. Know.

Syndromic infectious disease diagnostics from BioFire can help take the guesswork out of pathogen identification. Syndromic testing combines several potential targets into one rapid in vitro diagnostic test. Fast sample-to-answer turnaround combined with comprehensive menus helps inform timely optimal therapy.

Learn more about syndromic infectious disease testing from BioFire

Webinars

Publications and Posters

Supporting Documents

Other Available
BioFire® FilmArray® Panels

Pneumonia

Respiratory

Gastrointestinal

Meningitis

Joint Infection

Product availability varies by country. Consult your bioMérieux representative.

References:

  1. Messacar K, et al. Clinical Impact and Provider Acceptability of Real-Time Antimicrobial Stewardship Decision Support for Rapid Diagnostics in Children With Positive Blood Culture Results. J Ped Infect Dis Soc. 2017;6(3):267-274.
  2. Stated sensitivity and specificity is the aggregate performance from the prospective clinical study data.
  3. Barlam T, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Infectious Diseases Society of America. 2016;62(15 May).
  4. Banerjee R, et al. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015;61:1071-80.
  5. Pardo J, et al. Clinical and Economic Impact of Antimicrobial Stewardship Interventions with the FilmArray® Blood Culture Identification Panel. Diagn Microbiol Infect Dis. 2016;84(2):159–164.
*Data obtained with the previous version of the BIOFIRE BCID2 Panel